NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Diagnostics & Research · USD

Waters Corporation (WAT) Stock Analysis

Waters Corporation (WAT) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

WAT

$409.38

−$4.18 (−1.01%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare WAT with… →

WAT Key Statistics

As of Sep 4, 2026
Trading
Open
$408.66
Previous Close
$413.56
Day's Range
402.83–412.10
52-Week Range
282.77–426.22
Volume
352.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
Market Cap
$40.20B
P/E Ratio
104.17
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
24.74
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.54
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.65
EPS (ttm)Profit attributable to each share over the last twelve months.
3.93
Financials (FY)
Revenue (FY)
$3.17B+6.99%
Net Income (FY)
$642.63M+0.75%
Profit marginThe share of revenue left as profit after all costs and taxes.
3.59%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
98.19M
1-Year Return
+36.60%
Dividend and dates
Earnings Date
October 30, 2026
Avg Volume
838.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

WAT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.78%
2025+2.39%
2024+12.68%
2023−3.90%
2022−8.06%
2021+50.59%
2020+5.89%
2019+23.85%
2018−2.35%
2017+43.75%
2016 (partial year)−14.61%

As of September 4, 2026.

WAT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.17B$642.63M20.3%
2024$2.96B$637.83M21.6%
2023$2.96B$642.23M21.7%
2022$2.97B$707.76M23.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.17B$1.88B$802.59M$642.63M20.3%
2024$2.96B$1.76B$837.92M$637.83M21.6%
2023$2.96B$1.76B$817.68M$642.23M21.7%
2022$2.97B$1.72B$883.19M$707.76M23.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

WAT Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricWATDiagnostics & Research medianvs median
P/E104.1733.083.1x the median
P/S ratio8.654.9973% above
Profit margin3.59%0.00%3.6 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Waters Corporation (WAT) at $40.20B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 16,000.

Over the past 52 weeks the price has ranged from $282.77 to $426.22. WAT last closed at $409.38 on September 4, 2026. That is −$4.18 (−1.01%) against the previous close. The latest close sits 44.77% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $3.17B. Against the prior fiscal year total of $2.96B, that is a change of +6.99%. Net income for the same year was $642.63M. That is +0.75% against the prior fiscal year. Profit margin runs at 3.59%. That is 3.6 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 3.93.

Across the 4 fiscal years on file, revenue moves from $2.97B in 2022 to $3.17B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

WAT trades at a trailing price-to-earnings ratio of 104.17. That is 3.1 times the Diagnostics & Research median of 33.08. The forward P/E on file is 24.74. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.54. Measured against sales, the shares trade at 8.65 times revenue. On price-to-sales that is 73.43% above the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.19. Daily returns over the trailing 10 years annualize to a volatility of 30.94%. The trailing one-year price return is +36.60%. Measured over 10 years, that is +10.12% a year compounded.

Growth & Income

No dividend is on file for WAT.

The strongest complete calendar year on file is 2021 at +50.59%; the weakest is 2022 at −8.06%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +7.78% year to date.

Peer Comparison

Waters Corporation (WAT) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Waters Corporation WAT $40.20B 104.2
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Waters Corporation trades at a P/E of 104.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Waters Corporation

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Visit website →